Our aim is to show the clinical potential of inhibiting extracellular GzmB in the area of dermatology first, before attempting clinical development in other non-dermatological indications. Dermatology offersboth economical and timeline advantages with respect to moving our lead program into a clinical pathway for drug development and also provides opportunities to leverage our findings and explore other dermatological indications.




Discoid Lupus Erythematosus

Cutaneous Leishmaniasis

Skin Burns

Photoaging (Skin Aging)